GO:0070664 negative regulation of leukocyte proliferation: Immune Homeostasis, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070664 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of leukocyte proliferation.
• This term is a critical checkpoint in immune homeostasis, preventing excessive or misdirected leukocyte expansion that can lead to autoimmunity or hematological malignancies.
• Key molecular regulators include cell cycle inhibitors, ubiquitin ligases, metabolic enzymes such as PANK4, and transcription factors like RUNX2.
• Dysregulation of this process is implicated in tumor immune evasion, where leukocyte-specific protein 1 (LSP1) in T cells can regulate tumor growth.
• CRISPR knockout, point mutation, and overexpression models are essential to dissect the causal role of specific genes in this negative regulatory pathway.
• Understanding this GO term provides a foundation for developing therapies that modulate immune responses in cancer, autoimmunity, and inflammatory diseases.
Description
The Gene Ontology (GO) term GO:0070664, negative regulation of leukocyte proliferation, defines any process that stops, prevents, or reduces the frequency, rate or extent of leukocyte proliferation. Leukocytes, or white blood cells, are central to innate and adaptive immunity, and their proliferation must be tightly controlled to mount effective responses against pathogens while avoiding collateral tissue damage. This regulatory process is therefore a cornerstone of immune homeostasis and a focal point for understanding diseases ranging from autoimmunity to leukemia. Research into negative regulation of leukocyte proliferation has revealed a complex network of intracellular checkpoints, including cell cycle inhibitors, ubiquitin-dependent degradation pathways, and metabolic rewiring. For example, the transcription factor RUNX2 has been identified as a novel regulator of hematopoietic stem cell expansion and T-cell commitment, highlighting the interplay between differentiation and proliferation arrest. Similarly, leukocyte-specific protein 1 (LSP1) in T cells can regulate tumor growth, underscoring the physiological importance of negative regulation in cancer immunity. For researchers, GO:0070664 provides a structured framework to annotate gene functions and to design experiments that test how specific perturbations alter leukocyte expansion. This article synthesizes authoritative GO definitions with verified PubMed literature to outline the mechanisms, key genes, disease relevance, and CRISPR-based methods for studying negative regulation of leukocyte proliferation.
negative regulation of leukocyte proliferation At A Glance
| GO ID | GO:0070664 |
|---|---|
| GO term | negative regulation of leukocyte proliferation |
| Ontology | biological_process |
| Synonym | inhibition of leukocyte proliferation; downregulation of leukocyte proliferation; down-regulation of leukocyte proliferation; down regulation of leukocyte proliferation |
| Definition | Any process that stops, prevents, or reduces the frequency, rate or extent of leukocyte proliferation. |
| Major function | Maintains immune homeostasis by limiting excessive leukocyte expansion, preventing autoimmunity and hematological malignancies. |
| Related processes | Cell cycle arrest, apoptosis, immune tolerance, cytokine signaling, metabolic regulation. |
| Key regulators | RUNX2, LSP1, PANK4, ubiquitin ligases, CD28/B7 costimulatory pathway. |
| Disease relevance | Cancer immune evasion, autoimmune disorders, inflammatory diseases, hematopoietic malignancies. |
What Is GO:0070664?
In our own words, GO:0070664 encompasses any cellular or molecular event that decreases the frequency, rate, or extent of leukocyte proliferation. This includes processes that block cell cycle entry, promote cell cycle exit, induce apoptosis or senescence, or limit the availability of growth factors and metabolic substrates required for division. The term is a biological process and is synonymous with inhibition of leukocyte proliferation, downregulation of leukocyte proliferation, and down-regulation of leukocyte proliferation.
Why Is negative regulation of leukocyte proliferation Important in Cell Biology?
Negative regulation of leukocyte proliferation is essential for a balanced immune response. Without it, uncontrolled leukocyte expansion can lead to autoimmune tissue destruction, chronic inflammation, or leukemia. Conversely, insufficient negative regulation can impair the resolution of immune responses, while excessive suppression can permit tumor immune evasion. Understanding this process at the molecular level informs the development of immunotherapies, immunosuppressants, and cancer treatments.
• Prevents autoimmunity by restraining self-reactive leukocyte expansion.
• Limits chronic inflammation and tissue damage during infection.
• Controls hematopoietic stem cell expansion and T-cell commitment.
• Regulates tumor growth through T-cell-specific mechanisms.
• Influences immune evasion in pancreatic cancer via RBM47 and PDIA6.
• Modulates T-cell proliferation through metabolic pathways involving PANK4.
• Provides targets for immunosuppressive therapies in transplantation.
• Offers biomarkers for hematological malignancies.
• Guides CRISPR-based functional genomics screens for immune regulators.
• Informs development of exosome-based immunotherapies.
What Happens During negative regulation of leukocyte proliferation?
Initiation of negative signals
In simple terms: The process begins when a leukocyte receives signals that tell it to stop dividing.
Negative regulation is initiated by extracellular cues such as inhibitory cytokines, contact-dependent signals, or metabolic stress. For example, CD28/B7 costimulation can deliver both positive and negative signals that modulate T-cell proliferation. Ubiquitination pathways also play a role in T-cell development by targeting proliferative factors for degradation.
Cell cycle arrest
In simple terms: The cell's internal clock is halted, preventing it from entering the division cycle.
Once negative signals are received, cell cycle inhibitors such as p21, p27, and p53 are activated, leading to G1/S or G2/M arrest. RUNX2 has been identified as a regulator of hematopoietic stem cell expansion and T-cell commitment, influencing the balance between proliferation and differentiation. Metabolic enzymes like PANK4 control lipid synthesis and coenzyme A levels, which are required for T-cell proliferation; their inhibition leads to cell cycle arrest.
Apoptosis and survival signals
In simple terms: Some leukocytes are instructed to die, while others are kept alive but inactive.
Negative regulation can also involve the induction of apoptosis through intrinsic or extrinsic pathways. For instance, leukocyte-specific protein 1 (LSP1) in T cells regulates tumor growth, potentially by modulating survival signals. Ubiquitination controls the stability of pro- and anti-apoptotic proteins during T-cell development.
Metabolic checkpoints
In simple terms: The cell's metabolism is rewired to limit the energy and building blocks needed for division.
Metabolic checkpoints are critical for negative regulation. PANK4 modulates coenzyme A and glutaminolysis to control lipid synthesis for T-cell proliferation; its loss reduces proliferation. Similarly, RBM47 promotes cell proliferation and immune evasion by upregulating PDIA6 in pancreatic cancer, indicating that metabolic and ER stress pathways intersect with proliferative control.
Resolution and memory formation
In simple terms: After the threat is cleared, the immune response contracts, leaving memory cells for future protection.
Negative regulation ensures that the immune response is resolved and that a pool of memory T cells is maintained. This involves the contraction of effector T cells and the survival of a small subset. Exosomes derived from leukocyte-depleted red cell suspensions can regulate hematological tumor cells, suggesting a role for extracellular vesicles in this resolution phase.
Key Genes Involved in GO:0070664 negative regulation of leukocyte proliferation
The following genes and proteins have been experimentally linked to negative regulation of leukocyte proliferation, as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RUNX2 | Regulates hematopoietic stem cell expansion and T-cell commitment | Identified in a genome-wide screen as a novel regulator of T-cell development |
| LSP1 | Leukocyte-specific protein 1 in T cells; regulates tumor growth | Modulates T-cell proliferation and tumor immunity |
| PANK4 | Controls lipid synthesis for T-cell proliferation via CoA and glutaminolysis | Metabolic checkpoint for T-cell proliferation |
| RBM47 | Promotes cell proliferation and immune evasion by upregulating PDIA6 | Novel mechanism in pancreatic cancer progression |
| PDIA6 | Protein disulfide isomerase; downstream of RBM47 | Involved in immune evasion and proliferation |
| CD28 | Costimulatory receptor; delivers positive and negative signals | Modulates T-cell proliferation and tolerance |
| B7 | Ligand for CD28/CTLA-4; costimulatory molecule | Regulates T-cell activation and proliferation |
| Ubiquitin ligases | Target proliferative factors for degradation | Control T-cell development and proliferation |
| NF-κB | Transcription factor; can promote or inhibit proliferation | Downstream of CD28/B7 signaling |
| mTOR | Metabolic regulator; integrates signals for proliferation | Influences T-cell proliferation and negative regulation |
| FOXP3 | Regulatory T-cell transcription factor; suppresses proliferation | Maintains immune tolerance |
| CTLA-4 | Inhibitory receptor; competes with CD28 | Negative regulator of T-cell proliferation |
| PD-1 | Inhibitory receptor; limits T-cell proliferation | Target for cancer immunotherapy |
| IL-2 | Cytokine; promotes proliferation but also activation-induced cell death | Dual role in T-cell regulation |
| TGF-β | Cytokine; inhibits leukocyte proliferation | Suppresses immune responses |
| IL-10 | Cytokine; inhibits T-cell proliferation | Anti-inflammatory regulator |
| SOCS proteins | Suppress cytokine signaling | Negative feedback in leukocyte proliferation |
How Is negative regulation of leukocyte proliferation Regulated?
Negative regulation of leukocyte proliferation is itself controlled by multiple layers of regulation. The CD28/B7 costimulatory pathway provides both positive and negative signals that modulate T-cell proliferation, with CTLA-4 acting as a competitive inhibitor. Ubiquitination and deubiquitination dynamically control the stability of cell cycle regulators and transcription factors during T-cell development. Metabolic pathways, such as those involving PANK4 and coenzyme A, link nutrient availability to proliferative arrest. Additionally, cytokines like TGF-β and IL-10 suppress leukocyte proliferation, while transcription factors such as FOXP3 enforce regulatory T-cell function. These regulatory mechanisms ensure that leukocyte proliferation is tightly coupled to the context of infection, inflammation, and tissue homeostasis.
negative regulation of leukocyte proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RUNX2 | Hematopoietic malignancies, T-cell commitment defects | Knockout mouse models, CRISPR KO in hematopoietic stem cells |
| LSP1 | Tumor growth regulation, T-cell immunity | T-cell-specific knockout, overexpression in tumor models |
| PANK4 | T-cell proliferation defects, metabolic disorders | CRISPR KO in T cells, metabolic profiling |
| RBM47 | Pancreatic cancer progression, immune evasion | Knockdown/overexpression in pancreatic cancer cell lines |
| CD28/B7 | Autoimmunity, transplant rejection | Knockout mice, blocking antibodies |
Cancer and immune evasion
Negative regulation of leukocyte proliferation is often subverted in cancer. For example, RBM47 promotes cell proliferation and immune evasion by upregulating PDIA6 in pancreatic cancer, suggesting that this pathway can be hijacked to suppress anti-tumor immunity. LSP1 in T cells regulates tumor growth, indicating that T-cell-specific negative regulation influences cancer progression. Understanding these mechanisms can inform immunotherapies that restore negative regulation to prevent tumor escape.
Autoimmune and inflammatory diseases
Defects in negative regulation of leukocyte proliferation can lead to autoimmunity and chronic inflammation. The CD28/B7 costimulatory pathway is a key checkpoint; its dysregulation is associated with autoimmune disorders. Ubiquitination pathways that control T-cell development are also implicated in autoimmunity when perturbed. Enhancing negative regulation is a therapeutic strategy for suppressing pathological immune responses.
Hematological malignancies
Leukemias and lymphomas arise from uncontrolled leukocyte proliferation. Negative regulators such as RUNX2 are critical for hematopoietic stem cell expansion and T-cell commitment; their dysregulation can contribute to leukemogenesis. Exosomes derived from leukocyte-depleted red cell suspensions can regulate hematological tumor cells, highlighting a potential therapeutic avenue.
From negative regulation of leukocyte proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate leukocyte proliferation? | CRISPR knockout in primary T cells or Jurkat cells |
| Does a point mutation in gene X alter its function? | CRISPR point mutation knock-in in cell lines |
| Does overexpression of gene X suppress proliferation? | Lentiviral overexpression in leukocytes |
| Does gene X interact with metabolic pathways? | CRISPR KO combined with metabolomics |
| Does gene X regulate tumor immunity in vivo? | Adoptive transfer of KO T cells into tumor-bearing mice |
| Does gene X affect hematopoietic stem cell expansion? | CRISPR KO in HSCs followed by transplantation |
How to Study the negative regulation of leukocyte proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on proliferation | Identify novel negative regulators |
| Flow cytometry (CFSE/BrdU) | Cell division and proliferation rate | Quantify leukocyte proliferation |
| Metabolomics/Seahorse | Metabolic flux and substrate utilization | Assess metabolic checkpoints |
| RNA-seq | Transcriptional changes | Identify downstream targets |
| Western blot | Protein expression and signaling | Validate knockout/overexpression |
| Co-immunoprecipitation | Protein-protein interactions | Study ubiquitin ligase complexes |
| Exosome isolation and analysis | Extracellular vesicle cargo and function | Study regulation of hematological tumor cells |
| In vivo tumor models | Tumor growth and immune evasion | Test T-cell-specific gene functions |
CRISPR knockout screens
Genome-wide CRISPR knockout screens are powerful for identifying negative regulators of leukocyte proliferation. For example, a genome-wide screen identified RUNX2 as a novel regulator of hematopoietic stem cell expansion and T-cell commitment. Such screens can be performed in primary T cells or cell lines, with proliferation as the readout.
Flow cytometry and proliferation assays
Flow cytometry using CFSE or BrdU incorporation measures leukocyte proliferation directly. These assays can assess the effect of gene knockouts or overexpression on cell division. They are often combined with surface marker staining to distinguish T-cell subsets.
Metabolic profiling
Metabolic profiling, including Seahorse analysis and metabolomics, reveals how negative regulators affect glycolysis, glutaminolysis, and lipid synthesis. PANK4 was shown to control lipid synthesis for T-cell proliferation by modulating coenzyme A and glutaminolysis.
RNA sequencing and transcriptomics
RNA-seq can identify transcriptional changes upon perturbation of candidate genes. For instance, RBM47 upregulates PDIA6 to promote proliferation and immune evasion, a mechanism revealed by transcriptomic analysis. This method helps uncover downstream pathways.
How CRISPR Can Be Used to Study GO:0070664 negative regulation of leukocyte proliferation
Knockout
CRISPR knockout is used to delete candidate genes and assess whether their loss increases leukocyte proliferation, thereby confirming a negative regulatory role. For example, knockout of RUNX2 in hematopoietic stem cells affects expansion and T-cell commitment. Knockout of PANK4 impairs T-cell proliferation, indicating a positive role in proliferation rather than negative regulation.
Point Mutation
Point mutations can be introduced to mimic disease-associated variants or to abrogate specific domains. For instance, mutating ubiquitination sites on a negative regulator can stabilize it or prevent its degradation, altering proliferation. This approach helps dissect molecular mechanisms.
Knock-in
Knock-in of tagged versions of genes (e.g., GFP or HA) allows visualization and immunoprecipitation of the endogenous protein. This is useful for studying localization and interactions of negative regulators in leukocytes.
Overexpression
Overexpression of a candidate negative regulator can suppress leukocyte proliferation. For example, overexpression of LSP1 in T cells may reduce tumor growth. This approach validates gain-of-function effects and can identify therapeutic targets.
How EDITGENE Supports negative regulation of leukocyte proliferation Research
Researchers studying negative regulation of leukocyte proliferation-related genes often need to determine whether a candidate gene is causally involved in restraining leukocyte expansion. EDITGENE provides comprehensive CRISPR services to enable such functional studies with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of leukocyte proliferation research.
Frequently Asked Questions About negative regulation of leukocyte proliferation
What is negative regulation of leukocyte proliferation?
It is any biological process that stops, prevents, or reduces the frequency, rate, or extent of leukocyte proliferation, as defined by GO:0070664.
What genes are involved in negative regulation of leukocyte proliferation?
Key genes include RUNX2, LSP1, PANK4, RBM47, CD28, CTLA-4, and FOXP3, among others.
How is negative regulation of leukocyte proliferation studied?
It is studied using CRISPR knockout screens, flow cytometry, metabolic profiling, and RNA-seq.
Why is negative regulation of leukocyte proliferation important in cancer?
It prevents excessive immune cell expansion and can influence tumor immune evasion; its dysregulation is linked to cancer progression.
What diseases are associated with defects in negative regulation of leukocyte proliferation?
Autoimmune diseases, chronic inflammation, and hematological malignancies.
What is the role of RUNX2 in leukocyte proliferation?
RUNX2 was identified as a novel regulator of hematopoietic stem cell expansion and T-cell commitment.
How does PANK4 affect T-cell proliferation?
PANK4 controls lipid synthesis for T-cell proliferation by modulating coenzyme A and glutaminolysis.
Can CRISPR be used to study negative regulation of leukocyte proliferation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect gene function in this process.
What is the CD28/B7 costimulatory pathway?
It is a key pathway that provides positive and negative signals for T-cell activation and proliferation, reviewed by Greenfield et al..
How do exosomes regulate leukocyte proliferation?
Exosomes derived from leukocyte-depleted red cell suspensions can regulate hematological tumor cells, suggesting a role in negative regulation.
Conclusion
GO:0070664 negative regulation of leukocyte proliferation is a fundamental biological process that safeguards immune homeostasis by restraining excessive leukocyte expansion. Its molecular underpinnings involve a complex interplay of transcription factors, metabolic enzymes, ubiquitin ligases, and costimulatory signals. Dysregulation of this process contributes to cancer, autoimmunity, and hematological disorders, making it a rich area for therapeutic targeting. Advances in CRISPR-based functional genomics, combined with metabolic and transcriptomic profiling, are accelerating the discovery of novel regulators. EDITGENE's suite of CRISPR services empowers researchers to interrogate these mechanisms with precision, from knockout to overexpression models, ultimately driving innovations in immunotherapy and immune regulation.
References
- 1. Kwon R et al.. 2020. Regulation of tumor growth by leukocyte-specific protein 1 in T cells.. J Immunother Cancer 8(2) PMID: 33020243
- 2. Meaker GA et al.. 2025. A genome-wide screen identifies Runx2 as a novel regulator of hematopoietic stem cell expansion and T-cell commitment.. Blood 146(26):3188-3200 PMID: 40961240
- 3. Roodman GD. 2006. Regulation of osteoclast differentiation.. Ann N Y Acad Sci 1068:100-9 PMID: 16831910
- 4. Peng Z et al.. 2024. The Function of Ubiquitination in T-Cell Development.. Adv Exp Med Biol 1466:135-159 PMID: 39546141
- 5. Ma Y et al.. 2024. RBM47 promotes cell proliferation and immune evasion by upregulating PDIA6: a novel mechanism of pancreatic cancer progression.. J Transl Med 22(1):1164 PMID: 39741300
- 6. Hwang JR et al.. 2025. Pantothenate kinase 4 controls lipid synthesis for T-cell proliferation by modulating coenzyme A and glutaminolysis.. Signal Transduct Target Ther 10(1):302 PMID: 40962808
- 7. Greenfield EA et al.. 1998. CD28/B7 costimulation: a review.. Crit Rev Immunol 18(5):389-418 PMID: 9784967
- 8. Huang HB et al.. 2022. [Release of Exosomes Derived from Leukocyte-Depleted Red Cell Suspension and Its Regulation on Hematological Tumor Cells].. Zhongguo Shi Yan Xue Ye Xue Za Zhi 30(4):1188-1192 PMID: 35981382
